Eczema Clinical Trial
Official title:
Beneficial Effects of Paraffin Bath Therapy as Additional Treatment of Chronic Hand Eczema: A Randomized Controlled Trial
Verified date | August 2020 |
Source | Cairo University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Objective: Chronic Hand eczema (CHE) is a common inflammatory skin disease has a major medical psychological and socio‐economic implications that affect quality of life (QoL)and work ability. This study, the first randomized controlled trial that will be conducted to evaluate the effect of paraffin bath therapy (PBT) in the treatment of CHE.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 25, 2020 |
Est. primary completion date | November 12, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Age from 20-40 years - Time elapsed from the beginning of the disease ; more than three months according to the Guideline of the German Dermatological Society Exclusion Criteria: - active eczematous lesions on other parts of the body; - malignant or premalignant skin tumors |
Country | Name | City | State |
---|---|---|---|
Saudi Arabia | Zizi Mohammed Ibrahim Ali | Riyadh |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Saudi Arabia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | SCORAD ("SCORing Atopic Dermatitis | is the most widely clinical tool for assessing the severity (i.e. extent, intensity) of atopic dermatitis as objectively as possible.20 It consists of six objective items (erythema, oedema/papules, effect of scratching, oozing/crust formation, lichenification, and dryness), and two subjective symptoms (itch and sleeplessness), the maximum score is 103 points | Change from Baseline at SCORAD score at 6th week and at 12th weeks of treatment | |
Secondary | Dermatology life quality index (DLQI) | DLQI consists of ten questions describe symptoms, feelings, leisure activities, work or school activities, personal relationships and treatment | Change from Baseline at 6th week and at 12th weeks of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01257061 -
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment
|
Phase 3 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Recruiting |
NCT05439577 -
A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema
|
||
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02075632 -
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
|
Phase 2 | |
Completed |
NCT00143819 -
Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis
|
Phase 2 | |
Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04358224 -
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
|
Phase 4 | |
Not yet recruiting |
NCT04520308 -
An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis
|
Phase 4 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT04023084 -
Response of Children With Atopic Dermatitis (Eczema) to Eucrisa
|
Phase 4 | |
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Completed |
NCT05583019 -
Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)
|
||
Completed |
NCT03293030 -
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
|
Phase 4 | |
Completed |
NCT02002871 -
Blue Light for Treating Eczema
|
N/A | |
Completed |
NCT01420705 -
Bacille Calmette-Guérin (BCG) Vaccine and Atopy
|
N/A | |
Recruiting |
NCT01012453 -
A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema
|
N/A | |
Completed |
NCT00375713 -
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
|
Phase 3 |